HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Even-Sapir, E. Articles by Metser, U. Search for Related Content PubMed PubMed Citation Articles by Even-Sapir, E. Articles by Metser, U.

SPECT/Multislice Low-Dose CT: A Clinically Relevant Constituent in the Imaging Algorithm of Nononcologic Patients Referred for Bone Scintigraphy

¹ Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; ² Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; and ³ Musculoskeletal Radiology Unit, Department of Radiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Correspondence: For correspondence or reprints contact: Einat Even-Sapir, MD, PhD, Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, 6 Weizman St., Tel-Aviv, 64239 Israel. E-mail: evensap{at}tasmc.health.gov.il

The purpose of this prospective study was to assess the role of SPECT/multislice low-dose (Msl) CT as a constituent in the imaging algorithm of nononcologic patients referred for ^99mTc-methylene diphosphonate bone scintigraphy (BS). Methods: SPECT/CT was performed using a novel hybrid system, which incorporates a -camera and a multislice low-dose CT, on 76 consecutive nononcologic patients with nonspecific scintigraphic findings, which required further correlation with morphologic data. Results: SPECT/MslCT was of added clinical value in 89% of the patients. Characterizing scintigraphic lesions by their morphologic appearance, SPECT/MslCT reached a final diagnosis in 49 of 85 (58%) nonspecific scintigraphic bone lesions found in 59% (45/76) of patients, obviating the need to perform additional imaging. In another 30% of patients (23/76), SPECT/MslCT data optimized the patients' imaging algorithm as the performance of a full-dose CT, MRI, or labeled-leukocyte scintigraphy as the next imaging was based on its findings combined with the patient's clinical presentation. Conclusion: SPECT/MslCT is a clinically relevant constituent in the imaging algorithm of nononcologic patients referred for BS.

Key Words: fusion • SPECT • CT • SPECT/CT • bone

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				A. K. Buck, S. Nekolla, S. Ziegler, A. Beer, B. J. Krause, K. Herrmann, K. Scheidhauer, H.-J. Wester, E. J. Rummeny, M. Schwaiger, et al. SPECT/CT J. Nucl. Med., August 1, 2008; 49(8): 1305 - 1319. [Abstract] [Full Text] [PDF]

				B. Bybel, R. C. Brunken, F. P. DiFilippo, D. R. Neumann, G. Wu, and M. D. Cerqueira SPECT/CT Imaging: Clinical Utility of an Emerging Technology RadioGraphics, July 1, 2008; 28(4): 1097 - 1113. [Abstract] [Full Text] [PDF]